Guess (NYSE:GES) Exceeds Q1 Expectations
Contemporary clothing brand Guess (NYSE:GES) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 9.4% year on year to $647.8 million. The company expects next quarter's revenue to be around $760.4 million, close to analysts' estimates. Its non-GAAP loss of $0.44 per share was 36.2% above analysts' consensus estimates.
Is now the time to buy Guess? Find out in our full research report.
Revenue: $647.8 million vs analyst estimates of $632.7 million (9.4% year-on-year growth, 2.4% beat)
Adjusted EPS: -$0.44 vs analyst estimates of -$0.69 (36.2% beat)
Revenue Guidance for Q2 CY2025 is $760.4 million at the midpoint, roughly in line with what analysts were expecting
Management lowered its full-year Adjusted EPS guidance to $1.48 at the midpoint, a 3.9% decrease
Operating Margin: -5.1%, down from -3.4% in the same quarter last year
Free Cash Flow was -$96.42 million compared to -$44.02 million in the same quarter last year
Market Capitalization: $577.8 million
Carlos Alberini, Chief Executive Officer, commented, 'We are encouraged by our first quarter performance, which came in ahead of expectations across key metrics. Revenue grew 9% in U.S. dollars and 12% in constant currency, reflecting the successful integration of rag & bone and continued momentum in our wholesale businesses across Europe and the Americas. Disciplined expense management, combined with the better than expected top-line performance, enabled us to report operating results ahead of our guidance range, narrowing our loss for the quarter.'
Flexing the iconic upside-down triangle logo with a question mark, Guess (NYSE:GES) is a global fashion brand known for its trendy clothing, accessories, and denim wear.
A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Regrettably, Guess's sales grew at a sluggish 4.9% compounded annual growth rate over the last five years. This fell short of our benchmark for the consumer discretionary sector and is a tough starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Guess's annualized revenue growth of 7% over the last two years is above its five-year trend, but we were still disappointed by the results.
This quarter, Guess reported year-on-year revenue growth of 9.4%, and its $647.8 million of revenue exceeded Wall Street's estimates by 2.4%. Company management is currently guiding for a 3.8% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 3% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds.
Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.
Guess's operating margin has shrunk over the last 12 months and averaged 6.9% over the last two years. The company's profitability was mediocre for a consumer discretionary business and shows it couldn't pass its higher operating expenses onto its customers.
In Q1, Guess generated an operating margin profit margin of negative 5.1%, down 1.8 percentage points year on year. This reduction is quite minuscule and indicates the company's overall cost structure has been relatively stable.
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Guess's EPS grew at an astounding 183% compounded annual growth rate over the last five years, higher than its 4.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
In Q1, Guess reported EPS at negative $0.44, down from negative $0.27 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Guess's full-year EPS of $1.80 to shrink by 9.1%.
We were impressed by how significantly Guess blew past analysts' EPS expectations this quarter. We were also happy its revenue outperformed Wall Street's estimates. On the other hand, its EPS guidance for next quarter missed. Zooming out, we think this was a mixed quarter. The stock traded up 1.1% to $11.17 immediately after reporting.
Is Guess an attractive investment opportunity at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
America's Car-Mart (NASDAQ:CRMT) Delivers Strong Q1 Numbers, Stock Soars
Used-car retailer America's Car-Mart (NASDAQ:CRMT) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $370.2 million. Its GAAP profit of $1.26 per share was 46.1% above analysts' consensus estimates. Is now the time to buy America's Car-Mart? Find out in our full research report. Revenue: $370.2 million vs analyst estimates of $343.5 million (1.9% year-on-year growth, 7.8% beat) EPS (GAAP): $1.26 vs analyst estimates of $0.86 (46.1% beat) Adjusted EBITDA: $33.92 million vs analyst estimates of $25.12 million (9.2% margin, 35.1% beat) Operating Margin: 8.6%, up from 5.1% in the same quarter last year Free Cash Flow was $18.44 million, up from -$12.01 million in the same quarter last year Locations: 154 at quarter end, in line with the same quarter last year Same-Store Sales fell 3.9% year on year (-5.3% in the same quarter last year) Market Capitalization: $477 million With a strong presence in the Southern and Central US, America's Car-Mart (NASDAQ:CRMT) sells used cars to budget-conscious consumers. Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. With $1.39 billion in revenue over the past 12 months, America's Car-Mart is a small retailer, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with suppliers. On the bright side, it can grow faster because it has more white space to build new stores. As you can see below, America's Car-Mart grew its sales at a solid 13% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) despite not opening many new stores. This quarter, America's Car-Mart reported modest year-on-year revenue growth of 1.9% but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, a deceleration versus the last six years. Still, this projection is healthy and implies the market sees success for its products. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. America's Car-Mart listed 154 locations in the latest quarter and has kept its store count flat over the last two years while other consumer retail businesses have opted for growth. When a retailer keeps its store footprint steady, it usually means demand is stable and it's focusing on operational efficiency to increase profitability. The change in a company's store base only tells one side of the story. The other is the performance of its existing locations and e-commerce sales, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales provides a deeper understanding of this issue because it measures organic growth at brick-and-mortar shops for at least a year. America's Car-Mart's demand has been shrinking over the last two years as its same-store sales have averaged 2.7% annual declines. This performance isn't ideal, and we'd be concerned if America's Car-Mart starts opening new stores to artificially boost revenue growth. In the latest quarter, America's Car-Mart's same-store sales fell by 3.9% year on year. This decrease represents a further deceleration from its historical levels. We hope the business can get back on track. We were impressed by how significantly America's Car-Mart blew past analysts' revenue, EPS, and adjusted operating income expectations this quarter. Zooming out, we think this quarter featured some important positives. The stock traded up 6.9% to $61.75 immediately following the results. America's Car-Mart may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
3 Low-Volatility Stocks in Dangerous Territory
A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. Keeping that in mind, here are three low-volatility stocks to steer clear of and a few better alternatives. Rolling One-Year Beta: 0.87 With store associates called 'Zumiez Stash Members', Zumiez (NASDAQ:ZUMZ) is a specialty retailer of street and skate apparel, footwear, and accessories. Why Is ZUMZ Risky? Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand Poor expense management has led to operating margin losses Earnings per share have dipped by 57.7% annually over the past six years, which is concerning because stock prices follow EPS over the long term Zumiez is trading at $11.90 per share, or 45.1x forward P/E. To fully understand why you should be careful with ZUMZ, check out our full research report (it's free). Rolling One-Year Beta: 0.20 With roots dating back to 1877 when it introduced the first dental electric drill, Dentsply Sirona (NASDAQ:XRAY) manufactures and sells professional dental equipment, technologies, and consumable products used by dentists and specialists worldwide. Why Do We Avoid XRAY? Weak constant currency growth over the past two years indicates challenges in maintaining its market share Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 7% annually, worse than its revenue Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions At $16.16 per share, Dentsply Sirona trades at 8.5x forward P/E. Dive into our free research report to see why there are better opportunities than XRAY. Rolling One-Year Beta: 0.51 Powering the digital experiences of approximately 400 communications companies worldwide, Amdocs (NASDAQ:DOX) provides software and services that help telecommunications and media companies manage customer relationships, monetize services, and automate network operations. Why Do We Pass on DOX? New orders were hard to come by as its average backlog growth of 1.6% over the past two years underwhelmed Projected sales decline of 3.5% for the next 12 months points to an even tougher demand environment ahead Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 4.6 percentage points Amdocs's stock price of $92.92 implies a valuation ratio of 12.8x forward P/E. Read our free research report to see why you should think twice about including DOX in your portfolio, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.